This is a preview of subscription content, log in via an institution to check access.
Notes
2014 euros
Reference
Ruggeri M, et al. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy. PharmacoEconomics : 19 Mar 2018. Available from: URL: http://doi.org/10.1007/s40273-018-0643-4
Rights and permissions
About this article
Cite this article
Allopurinol/lesinurad cost effective for gout/hyperuricaemia. PharmacoEcon Outcomes News 800, 11 (2018). https://doi.org/10.1007/s40274-018-4830-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4830-5